Cat. No. 3495
Chemical Name: 9-β-D-Arabinofuranosyl-2-fluoro-9H-p
Biological ActivityPurine analog that inhibits DNA synthesis. Exhibits antiproliferative activity (IC50 = 1.54 μM in RPMI cells) and triggers apoptosis through increasing Bax and decreasing Bid, XIAP and survivin expression. Inhibits cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in lymphocytes. Also displays anticancer activity against hematological malignancies in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Bellosillo et al (1999) In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94 2836. PMID: 10515887.
Frank et al (1999) Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat.Med. 5 444. PMID: 10202937.
Meng et al (2007) Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo. Eur.J.Haematol. 79 486. PMID: 17976186.
Torella et al (2007) Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. Am.J.Physiol.Heart Circ.Physiol. 292 H2935. PMID: 17293493.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Fludarabine, supplier, Purine, analog, inhibits, inhibitors, DNA, synthesis, Proapoptotic, increases, Bax, decreases, Bid, XIAP, survivin, expression, Apoptosis, Inducer, STAT1, Tocris Bioscience, DNA, RNA and Protein Synthesis Inhibitors
Find multiple products by catalog number
New Products in this Area
Potent inhibitor of Aβ oligomer and fibril formationLDN 193188
Inhibitor of phosphatidylcholine transfer protein (PC-TP)Hydroxychloroquine sulfate
Autophagy inhibitor; also TLR9 inhibitor
March 19 - 23, 2016
Denver, CO, USA